Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 74Pancreatic Neoplasms 54Carcinoma, Non-Small-Cell Lung 29Triple Negative Breast Neoplasms 27Neoplasm Metastasis 16Squamous Cell Carcinoma of Head and Neck 15Ovarian Neoplasms 12Neoplasms 12Lung Neoplasms 11Esophageal Squamous Cell Carcinoma 11Stomach Neoplasms 10Esophageal Neoplasms 10Head and Neck Neoplasms 9Uterine Cervical Neoplasms 7Melanoma 7Cholangiocarcinoma 7Small Cell Lung Carcinoma 6Recurrence 6Sarcoma 5Pancreatic Adenocarcinoma 5Inflammatory Breast Neoplasms 5Fallopian Tube Neoplasms 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 4Advanced Pancreatic Cancer 4Carcinoma, Transitional Cell 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms, Male 3Adenocarcinoma 3Uveal Melanoma 2

Interventions

Gemcitabine 26Capecitabine 16Oxaliplatin 14Fluorouracil 13Cisplatin 12Leucovorin 9pembrolizumab 5Erlotinib Hydrochloride 5Bevacizumab 5durvalumab 4Trastuzumab 4Specimen Handling 4Sorafenib 4Magnetic Resonance Spectroscopy 4130-nm albumin-bound paclitaxel 4trifluridine tipiracil drug combination 3Lapatinib 3Irinotecan 3Carboplatin 3Biopsy 3tremelimumab 2toripalimab 2regorafenib 2lenvatinib 2dehydroftorafur 2cobimetinib 2atezolizumab 2anlotinib 2Nivolumab 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Gallbladder Neoplasms × Albumin-Bound Paclitaxel × Clear all
NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02392637 2022-02-02

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

M.D. Anderson Cancer Center

Phase 2 Completed
62 enrolled 10 charts
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡